XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Information
The following table summarizes segment information for the three and nine months ended September 30, 2024, and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net revenues:
Clinical Services$145,783 $127,553 $421,706 $365,578 
Advanced Diagnostics22,041 24,401 66,860 70,513 
Total revenue167,824 151,954 488,566 436,091 
Cost of revenue:
Clinical Services(1)
80,058 73,994 234,996 213,032 
Advanced Diagnostics(2)
12,886 15,649 40,727 46,043 
Total cost of revenue92,944 89,643 275,723 259,075 
Gross Profit:
Clinical Services65,725 53,559 186,710 152,546 
Advanced Diagnostics9,155 8,752 26,133 24,470 
Total gross profit$74,880 $62,311 $212,843 $177,016 
(1) Clinical Services cost of revenue adjustments for the three months ended September 30, 2024 includes $4.3 million of amortization of acquired intangible assets and $0.2 million of stock-based compensation. Clinical Services cost of revenue adjustments for the three months ended September 30, 2023 includes $4.3 million of amortization of acquired intangible assets. Clinical Services cost of revenue adjustments for the nine months ended September 30, 2024 includes $13.0 million of amortization of acquired intangible assets and $0.7 million of stock-based compensation. Clinical Services cost of revenue adjustments for the nine months ended September 30, 2023 includes $12.8 million of amortization of acquired intangible assets. There were no stock-based compensation amounts recorded for the three and nine months ended September 30, 2023.
(2) Advanced Diagnostics cost of revenue adjustments for the three months ended September 30, 2024 includes $0.6 million of amortization of acquired intangible assets and $0.1 million of stock-based compensation. Advanced Diagnostics cost of revenue adjustments for the three months ended September 30, 2023 includes $0.6 million of amortization of acquired intangible assets. Advanced Diagnostics cost of revenue adjustments for the nine months ended September 30, 2024 includes $1.8 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Advanced Diagnostics cost of revenue adjustments for the nine months ended September 30, 2023 includes $1.8 million of amortization of acquired intangible assets. There were no stock-based compensation amounts recorded for the three and nine months ended September 30, 2023.